| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 Feb 2026 | 18 Feb 2026 |
| Preferential Issue of shares & Inter alia, to consider the following businesses: 1. Consider and discuss alteration in the Articles of Association of the company subject to approval of shareholders. 2. Consider and discuss the proposal for fund raising by way of preferential issue/private placement of securities for cash, including determination of issue price subject to such regulatory/statutory approvals as may be required, including the approval of shareholders of the company. 3. Consider and discuss any other routine matter or business of the company. Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2026 ,inter alia, to consider and approve - Consider and discuss alteration in the Articles of Association of the company subject to approval of shareholders. - Consider and discuss the proposal for fund raising by way of preferential issue/private placement of securities for cash, including determination of issue price subject to such regulatory/statutory approvals as may be required, including the approval of shareholders of the company. - Consider and discuss any other routine matter or business of the company. Further, we wish to inform that in pursuance of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Companys Code of Conduct for Regulating, Monitoring, and Reporting of Trading by Insiders, the Trading Window for dealing in the shares of the company shall closed for all Designated Person and their immediate relatives from the date of this letter, i.e. February 18, 2026 till 48 hours from the conclusion of the Board Meeting. The Board considered and approved: Alteration of Article 15 of the Articles of Association of the Company. To issue, offer and allot upto 75,00,000 Equity Shares and 50,00,000 Convertible Warrants on preferential basis to the persons belonging to the Promoters and Non-Promoter Category at such price as determined in accordance with the provision of the SEBI (ICDR)Regulations, 2018 as amended from time to time, subject to the approval of shareholders of the Company. Convening of Extraordinary General Meeting (EGM) of the members of the company on Friday, March 20, 2026 through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). Appointment of Mr. Mast Ram Chechi proprietor of M/s. M.R. Chechi and Associates, Practicing Company Secretaries as Scrutinizer to scrutinize the e-voting process of Extraordinary General Meeting in fair and transparent manner; (As Per BSE Announcement Dated on:23.02.2026) | ||
| Board Meeting | 13 Feb 2026 | 7 Feb 2026 |
| Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve the Unaudited Standalone Financial Results of the company along with the Limited Review Report for the quarter ended 31st December 2025 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 13th February, 2026) which commenced at 01:00 P.M. and concluded at 05:30 P.M. have inter alia approved the following: ? The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter ended 31st December, 2025 along with the Limited Review Report duly signed by the Auditors of the company. You are requested to kindly take the same on record and oblige. Thanking You. (As Per BSE Announcement Dated on 13.02.2026) | ||
| Board Meeting | 14 Nov 2025 | 6 Nov 2025 |
| Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Consider approve and take on record the Unaudited Standalone Financial Results of the company along with the Limited Review Report for the quarter and half year ended 30th September 2025 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Consider and discuss any other routine matter or business of the company. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 14th November, 2025) which commenced at 03:30 P.M. and concluded at 06:00 P.M. have inter alia approved the following: ? The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter and half year ended 30th September, 2025 alongwith the Limited Review Report duly signed by the Auditors of the company. You are requested to kindly take the same on record and oblige. Thanking You. (As Per BSE Announcement Dated on 14.11.2025) Dear Sir/Madam, With reference to the email dated 21st November, 2025, please find attached revised outcome of the Board meeting held on 14th November, 2025. You are requested to take the same on record and oblige. Thanking You. (As Per BSE Announcement Dated on: 21/11/2025) | ||
| Board Meeting | 5 Sep 2025 | 1 Sep 2025 |
| Inter alia, to consider and approve:- 1. To consider and approve the Directors Report along with all necessary annexures thereof, for the Financial Year ended March 31, 2025; 2. To consider and fix day, date, time for holding the 23rd Annual General Meeting of the company and approve the notice of the same; 3. To consider and fix the date for closure of Register of Members and Share Transfer Books for the purpose of Annual General Meeting; 4. To appoint scrutinizer to conduct e-voting and poll process of 23rd Annual General Meeting of the company; 5. To consider and recommend the ratification of appointment of M/s. Garg Mendiratta and Associates, Chartered Accountants as the statutory auditors of the company in place of M/s. Harjeet Parvesh and Company, Chartered Accountants. 6. To consider and discuss any other routine matter or business of the company. ear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the attached outcome of Board Meeting held today (i.e. 05th September, 2025) which commenced at 01:00 P.M. and concluded at 05:30 P.M. You are requested to kindly take the same on record and oblige. Thanking You (As per BSE Announcement Dated on 05/09/2025) | ||
| Board Meeting | 14 Aug 2025 | 7 Aug 2025 |
| Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve 1. The Unaudited Standalone Financial Results of the company along with the Limited Review Report for the quarter ended 30th June 2025 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 14th August, 2025) which commenced at 01:30 P.M. and concluded at 02:30 P.M. have inter alia approved the following: ? The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter ended 30th June, 2025 alongwith the Limited Review Report duly signed by the Auditors of the company. You are requested to kindly take the same on record and oblige. Thanking You. (As Per BSE Announcement Dated on: 14.08.2025) Dear Sir/Madam, Pursuant to your email dated 11th September, 2025 please find the attached revised outcome of Board Meeting held on 14th August, 2025. Thanking You. (As Per Bse Announcement dated on 12/09/2025) | ||
| Board Meeting | 4 Aug 2025 | 4 Aug 2025 |
| Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Board of Directors at their meeting held today (i.e. 04th August, 2025) which commenced at 04:00 P.M. and concluded at 04:30 P.M. have inter alia approved the following: ? To appoint M/s. Garg Mendiratta and Associates, Chartered Accountants as the statutory auditors of the company in place of M/s. Harjeet Parvesh and Company, Chartered accountant and fix their remuneration. You are requested to kindly take the same on record and oblige. Thanking You | ||
| Board Meeting | 16 Jul 2025 | 16 Jul 2025 |
| Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Board of Directors at their meeting held today (i.e. 16th July, 2025) which commenced at 03:30 P.M. and concluded at 04:00 P.M. have inter alia approved the following: ? To accept the resignation of M/s. Harjeet Parvesh and Company, Chartered Accountants, Statutory Auditors of the company. You are requested to kindly take the same on record and oblige. Thanking You. | ||
| Board Meeting | 28 May 2025 | 20 May 2025 |
| Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 inter alia to consider and approve Dear Sir/Madam With reference to the captioned subject and in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the meeting of the Board of Directors of M/s. Prism Medico and Pharmacy Limited (hereinafter referred as the Company) is scheduled to be held at the registered office of the company i.e. Suketi Road Kala Amb Sirmaur Himachal Pradesh-173030 on Wednesday the 28th day of May 2025 at 03:00 P.M. inter alia to: - Consider approve and take on record the Audited Standalone Financial Results of the company along with the Auditors Report for the quarter and financial year ended 31st March 2025 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. - Consider and discuss any other routine matter or business of the company. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You. Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 28th May, 2025) which commenced at 03:00 P.M. and concluded at 04:30 P.M. have inter alia approved the following: ? The Board considered and approved the Audited Standalone Financial Results of the company along with the Auditors Report for the quarter and financial year ended 31st March, 2025 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. You are requested to kindly take the same on record and oblige. Thanking You. (As Per BSE Announcement Dated on: 28.05.2025) Dear Sir/Madam, With reference to the email dated 26th June, 2025 received from the stock exchange please find the attached revised outcome of Board Meeting held on 28th May, 2025. You are requested to take the same on record and oblige. Thanking You. (As Per BSE Announcement Dated on: 01/07/2025) | ||
| Board Meeting | 15 Apr 2025 | 15 Apr 2025 |
| Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors of the company at their meeting held today (i.e. 15th April, 2025) which commenced at 03:00 P.M. and concluded at 03:30 P.M. have inter alia approved the following: 1. To appoint Mr. Harpreet Singh of M/s. S Harpreet and Associates, Chartered Accountants, as internal auditors of the company for the financial year 2024-2025. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You. | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
